An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.

Genetic mutations that give rise to active mutant forms of Ras are oncogenic and found in several types of tumor. However, such mutations are not clear biomarkers for disease, since they are frequently detected in healthy individuals. Instead, it has become clear that elevated levels of Ras activity are critical for Ras-induced tumorigenesis. However, the mechanisms underlying the production of pathological levels of Ras activity are unclear. Here, we show that in the presence of oncogenic Ras, inflammatory stimuli initiate a positive feedback loop involving NF-κB that further amplifies Ras activity to pathological levels. Stimulation of Ras signaling by typical inflammatory stimuli was transient and had no long-term sequelae in wild-type mice. In contrast, these stimuli generated prolonged Ras signaling and led to chronic inflammation and precancerous pancreatic lesions (PanINs) in mice expressing physiological levels of oncogenic K-Ras. These effects of inflammatory stimuli were disrupted by deletion of inhibitor of NF-κB kinase 2 (IKK2) or inhibition of Cox-2. Likewise, expression of active IKK2 or Cox-2 or treatment with LPS generated chronic inflammation and PanINs only in mice expressing oncogenic K-Ras. The data support the hypothesis that in the presence of oncogenic Ras, inflammatory stimuli trigger an NF-κB-mediated positive feedback mechanism involving Cox-2 that amplifies Ras activity to pathological levels. Because a large proportion of the adult human population possesses Ras mutations in tissues including colon, pancreas, and lung, disruption of this positive feedback loop may be an important strategy for cancer prevention.

[1]  S. Pandol,et al.  Early NF-κB activation is associated with hormone-induced pancreatitis. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[2]  Xinghua Lu,et al.  Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. , 2002, Chinese medical journal.

[3]  E. Ranheim,et al.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. , 2011, Blood.

[4]  G. Green,et al.  Interaction of dietary protein and trypsin inhibitor on plasma cholecystokinin and pancreatic growth in rats. , 1986, Advances in experimental medicine and biology.

[5]  B. Ji,et al.  Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  K. Guan,et al.  Activation of MAP kinase kinase (MEK) and Ras by cholecystokinin in rat pancreatic acini. , 1995, The American journal of physiology.

[7]  I. Goldfine,et al.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. , 1985, The Journal of clinical investigation.

[8]  M. Korc,et al.  Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. , 2009, Biochemical and biophysical research communications.

[9]  S. Dey,et al.  Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. , 2005, Cancer research.

[10]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[11]  Y. Motoo Antiproteases in the treatment of chronic pancreatitis. , 2007, JOP : Journal of the pancreas.

[12]  B. Ji,et al.  Robust acinar cell transgene expression of CreErT via BAC recombineering , 2008, Genesis.

[13]  A. Levitzki,et al.  Residues crucial for Ras interaction with GDP-GTP exchangers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Lewis A. Chodosh,et al.  Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis , 2007, Nature Cell Biology.

[15]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[16]  T. Ishikawa,et al.  Transgenic mouse for conditional, tissue‐specific Cox‐2 overexpression , 2006, Genesis.

[17]  T. Wirth,et al.  Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo. , 2007, The Journal of clinical investigation.

[18]  C. Der,et al.  Guanine nucleotide exchange factors: Activators of Ras superfamily proteins , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  C. Lang,et al.  CCK-induced pancreatic growth is not limited by mitogenic capacity in mice. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[20]  Huamin Wang,et al.  Ras activity levels control the development of pancreatic diseases. , 2009, Gastroenterology.

[21]  D. Tuveson,et al.  RAS in cellular transformation and senescence. , 2009, European journal of cancer.

[22]  Jen Jen Yeh,et al.  Targeting signal transduction in pancreatic cancer treatment , 2007, Expert opinion on therapeutic targets.

[23]  John A. Williams,et al.  Calcineurin mediates pancreatic growth in protease inhibitor-treated mice , 2004 .

[24]  G. Manes,et al.  Helicobacter pylori and pancreatic disease. , 2003, JOP : Journal of the pancreas.

[25]  A. Dabrowski,et al.  Calcineurin-dependent and Calcineurin-independent Signal Transduction Pathways Activated as Part of Pancreatic Growth , 2006, Pancreas.

[26]  B. Göke,et al.  Regulation of HSP60 and the role of MK2 in a new model of severe experimental pancreatitis , 2009 .

[27]  T. Jacks,et al.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Owen,et al.  Ras binding to a C‐terminal region of GAP , 1995, FEBS letters.

[29]  P. Treuting,et al.  Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. , 2006, Cancer research.

[30]  M. Karin,et al.  Loss of Ikkβ Promotes Migration and Proliferation of Mouse Embryo Fibroblast Cells* , 2006, Journal of Biological Chemistry.

[31]  C. Qian,et al.  Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism. , 2004, Blood.

[32]  M. Korc,et al.  Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. , 1978, The American journal of physiology.

[33]  C. Niederau,et al.  Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice. , 1987, Gut.

[34]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[35]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[36]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Barbacid,et al.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.

[38]  H. Reber,et al.  Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. , 2007, Cancer research.

[39]  F. Meng,et al.  K-RAS mutation in the screening, prognosis and treatment of cancer. , 2009, Biomarkers in medicine.

[40]  G. Gurda,et al.  Regulator of calcineurin 1 controls growth plasticity of adult pancreas. , 2010, Gastroenterology.

[41]  Z. Ronai,et al.  High frequency of K‐ras mutations in normal appearing lung tissues and sputum of patients with lung cancer , 1995, International journal of cancer.

[42]  D. Coppola,et al.  IκB Kinase ε expression in pancreatic ductal adenocarcinoma. , 2011, American journal of clinical pathology.

[43]  W. Greenhalf,et al.  Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. , 2005, Gastroenterology.

[44]  D. Lowy,et al.  Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. , 1988, Science.

[45]  J. Downward,et al.  Many faces of Ras activation. , 2008, Biochimica et biophysica acta.

[46]  C. Verbeke,et al.  Cyclooxygenase-2 Expression Associated with Severity of PanIN Lesions: A Possible Link between Chronic Pancreatitis and Pancreatic Cancer , 2005, Pancreatology.

[47]  Jicheng Li,et al.  A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. , 2003, World journal of gastroenterology.